# US 2024/0197787 A1 · Method for treating acute respiratory distress syndrome (ards) in specific patients using mesenchymal lineage precursor or stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197787 A1
- Document ID: US20240197787A1
- Status: Published application
- Kind: A1
- Application number: 18/556,827
- Filed: 2022-04-22
- Published: 2024-06-20
- Earliest claimed: 2021-04-23
- Applicants: Mesoblast International SáRl
- Inventors: Silviu ITESCU
- Web page: https://patentgrep.com/patent/US20240197787A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods for treating or preventing Acute Respiratory Distress Syndrome (ARDS) in a subject in need thereof, the method comprising administering to the subject a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs).

## Claims

### Claim 1

A method of treating Acute Respiratory Distress Syndrome (ARDS) in a human subject in need thereof, the method comprising selecting a subject with ARDS who is greater than or equal to 65 years old and, administering to the subject greater than 4 million mesenchymal lineage precursor or stem cells (MLPSCs) per kilogram of body weight (cells/kg).

### Claim 2 (depends on 1)

The method according to claim 1, wherein the subject has increased inflammatory biomarkers which indicate:
(a) increased neutrophil and macrophage influx into lungs influx;
(b) increased macrophage inflammation and augmented neutrophil migration to lungs; and/or,
(c) T cell activation/proliferation and apoptotic death.

### Claim 3

A method of treating Acute Respiratory Distress Syndrome (ARDS) in a human subject in need thereof, the method comprising selecting a subject with ARDS who has increased inflammatory biomarkers which indicate:
(a) increased neutrophil and macrophage influx into lungs;
(b) increased macrophage inflammation and augmented neutrophil migration to lungs; and/or,
(c) T cell activation/proliferation and apoptotic death, and, administering to the subject a greater than 4 million mesenchymal lineage precursor or stem cells (MLPSCs) per kilogram of body weight (cells/kg).

### Claim 4 (depends on 1, 2, 3)

The method according to any one of claims 1 to 3, wherein the subject is on a ventilator.

### Claim 5 (depends on 2, 3, 4)

The method according to any one of claims 2 to 4, wherein the inflammatory biomarkers which indicate increased neutrophil and macrophage influx into lungs are CCR2- or CXCR3-binding chemokines.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the CCR2-binding chemokine(s) is CCL2, CCL3, or CCL7, preferably CCL2.

### Claim 7 (depends on 5)

The method according to claim 5, wherein CXCR3-binding chemokine is CXCL10 or CXCL9, preferably CXCL10.

### Claim 8 (depends on 2, 3, 4, 5, 6, 7)

The method according to any one of claims 2 to 7, wherein the inflammatory biomarkers which indicate increased macrophage inflammation and augmented neutrophil migration to lungs are IL-6 or IL-8.

### Claim 9 (depends on 2, 3, 4, 5, 6, 7, 8)

The method according to any one of claims 2 to 8, wherein the inflammatory biomarkers which indicate T cell activation/proliferation and apoptotic death are CCL19 or IL-2.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method according to any one of claims 1 to 9, wherein the subject's level of inflammatory biomarker(s) are increased relative to a subject who is less than 65 years old.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the subject's level of inflammatory biomarker(s) are increased by at least 2 fold relative to a subject who is less than 65 years old.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the subject's level of inflammatory biomarker(s) are increased by at least 5 fold relative to a subject who is less than 65 years old.

### Claim 13 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method according to any one of claims 3 to 12, wherein the subject is greater than or equal to 65 years old.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method according to any one of claims 1 to 13, wherein the subject has persistent CRP levels after being administered a first dose of MLPSCs which comprises less than 4 million MLPSCs per kilogram of body weight (cells/kg).

### Claim 15 (depends on 14)

The method according to claim 14, wherein the subject has persistent CRP levels 3 days after being administered the first dose of MLPSCs.

### Claim 16 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method according to any one of claims 4 to 15, wherein the subject is taken off the ventilator after treatment.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the subject is taken off a ventilator within 60 days of treatment.

### Claim 18

A method of treating or preventing Acute Respiratory Distress Syndrome (ARDS) in a human subject in need thereof, the method comprising:
determining or having determined a subject's level of one or more inflammatory biomarkers selected from the list comprising: (i) a CXCR3 binding chemokine, preferably CXCL10, and/or CXCL9; (ii) a CCR2-binding chemokine, preferably CCL2, CCL3, and/or CCL7; (iii) IL-6; (v) IL-8; (vi) CCL19; (vii) IL-2; and/or (viii) CRP;
selecting a subject who:
is greater than or equal to 65 years old; and/or,
has an increased level of one or more inflammatory biomarkers relative to a subject who is less than 65 years old; and/or,
has persistent CRP levels 3 days after being administered a first dose of mesenchymal lineage precursor or stem cells (MLPSCs) which comprises less than 4 million MLPSCs per kilogram of body weight (cells/kg); and
administering to the subject greater than 4 million mesenchymal lineage precursor or stem cells (MLPSCs) per kilogram of body weight (cells/kg).

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method according to any one of claims 1 to 18 wherein, treatment decreases the level of at least one inflammatory biomarker(s) relative to baseline, wherein the at least one inflammatory biomarker(s) indicate:
(a) reduced neutrophil and macrophage influx into lungs;
(b) reduced inflammasome;
(c) reduced macrophage activation and neutrophil migration to lungs;
(d) reduced T cell influx and activation; or
(e) reduced circulating biomarkers of macrophage and neutrophil inflammation.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the inflammatory biomarker(s) is one or more of the following:
a CXCR3-binding chemokine, preferably CXCL10, and/or CXCL9;
CCR2-binding chemokine, preferably CCL2, CCL3, and/or CCL7;
IL-6;
IL-8;
TNF;
IL-18;
CCL19;
IL-4;
IL-13;
GM-CSF;
CRP; or
Ferritin.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method according to any one of claims 1 to 20, wherein treatment reduces CRP and/or ferritin levels within 3 to 14 days of administering greater than 4 million MLPSCs per kilogram of body weight (cells/kg).

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method according to any one of claims 1 to 21, wherein treatment improves respiratory function in the subject.

### Claim 23 (depends on 22)

The method according to claim 22, wherein respiratory function as defined by Berlin criteria is improved at day 14 and/or day 21.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method according to any one of claims 1 to 23, wherein the subject is administered greater than 5 million MLPSCs/kg, greater than 6 million MLPSCs/kg, or greater than 8 million MLPSCs/kg.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method according to any one of claims 1 to 24, wherein the greater than 4 million MLPSCs/kg is administered over at least 2 to 3 doses.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the subject receives greater than 4 million MLPSCs per kilogram of body weight (cells/kg) within 5 to 9 days of being administered a first dose.

### Claim 27 (depends on 25)

The method according to claim 25, wherein the subject receives greater than 4 million MLPSCs per kilogram of body weight (cells/kg) within 7 days of being administered a first dose.

### Claim 28 (depends on 25, 26, 27)

The method according to any one of claims 25 to 27 which comprises administering between 1×108 and 2.5×108 MLPSCs per dose.

### Claim 29 (depends on 25, 26, 27)

The method according to any one of claims 25 to 27 which comprises administering about 1.6×108 MLPSCs per dose.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method according to any one of claims 1 to 29, wherein the subject is also taking a corticosteroid.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method according to any one of claims 1 to 29, further comprising administering a corticosteroid.

### Claim 32 (depends on 30, 31)

The method according to any one of claims 30 or 31, wherein the corticosteroid is dexamethasone.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method according to any one of claims 1 to 32, wherein the ARDS is moderate or severe.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method according to any one of claims 1 to 33, wherein the ARDS is caused by a viral infection such as a rhinovirus, an influenza virus, a respiratory syncytial virus (RSV) or a coronavirus.

### Claim 35 (depends on 34)

The method according to claim 34, wherein the viral infection is caused by a coronavirus.

### Claim 36 (depends on 35)

The method according to claim 35, wherein the coronavirus is Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), Middle East Respiratory Syndrome coronavirus (MERS-CoV) or COVID-19.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method according to any one of claims 1 to 36, wherein the MLPSCs have been cryopreserved and thawed.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method according to any one of claims 1 to 37, wherein the MLPSCs are culture expanded from an intermediate cryopreserved MLPSCs population.

### Claim 39 (depends on 38)

The method according to claim 38, wherein the MLPSCs are culture expanded for at least about 5 passages.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method according to any one of claims 1 to 39, wherein the MLPSCs express at least 13 pg TNFR1 per million MLPSCs.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method according to any one of claims 1 to 40, wherein the MLPSCs express about 13 pg to about 44 pg TNFR1 per million MLPSCs.

### Claim 42 (depends on 38, 39, 40, 41)

The method according to any one of claims 38 to 41, wherein said culture expansion comprises at least 20 or 30 population doublings.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method according to any one of claims 1 to 42, wherein the MLPSCs are mesenchymal stem cells (MSCs).

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method according to any one of claims 1 to 43, wherein the MLPSCs are allogeneic.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method according to any one of claims 1 to 44, wherein the MLPSCs are modified to carry or express an anti-viral drug or thrombolytic agent.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method according to any one of claims 1 to 45, wherein the MLPSCs are administered in a composition(s) which comprises Plasma-Lyte A, dimethyl sulfoxide (DMSO), human serum albumin (HSA).

### Claim 47 (depends on 46)

The method according to claim 46, wherein the composition comprises Plasma-Lyte A (70%), DMSO (10%), HSA (25%) solution, the HSA solution comprising 5% HSA and 15% buffer.

### Claim 48 (depends on 46, 47)

The method according to claim 46 or 47, wherein the composition comprises greater than 6.68×106 viable cells/mL.

### Claim 49

A method of treating Acute Respiratory Distress Syndrome (ARDS) in a human subject in need thereof, the method comprising:
administering to the subject 4 million mesenchymal lineage precursor or stem cells (MLPSCs) per kilogram of body weight (cells/kg);
determining or having determined the subject's level of one or more biomarkers selected from the group consisting of CXCL10, CXCL9, CCL2, CCL3, CCL7, IL-6, IL-8, CCL19, IL-2, ferritin and/or CRP relative to a baseline level of the biomarker(s) prior to administering MLPSCs;
administering a further dose of MLPSCs to the subject if the level of one or more biomarkers does not decrease from baseline, wherein following the further dose, the subject has been administered greater than 4 million mesenchymal lineage precursor or stem cells (MLPSCs) per kilogram of body weight (cells/kg).

### Claim 50 (depends on 49)

The method according to claim 49, wherein the biomarker is CRP and/or ferritin.

### Claim 51 (depends on 49)

The method according to claim 49, wherein the subject's level of CRP and/or ferritin is determined relative to baseline at day 7 and/or day 14.

### Claim 52 (depends on 49, 50, 51)

The method according to any one of claims 49 to 51, wherein the further dose comprises 2 million MLPSCs per kilogram of body weight (cells/kg).
